The Latest Cardiac and Vascular News
SoniVie announces enrollment completion in the REDUCED-1 pilot study TEL AVIV, Israel, Jan. 31, 2024 /PRNewswire/ — SoniVie, an Israeli company developing a novel, proprietary Therapeutic Intra-Vascular Ultrasound (TIVUSTM) System to treat a variety of hypertensive disorders, announced…
The funds, provided by new investors and current shareholder, will be used to support the Company clinical and regulatory path towards pre-market approval of its TIVUS™ technology for the treatment of hypertension TEL AVIV, Israel, Jan. 9, 2023 /PRNewswire/ — SoniVie Ltd. (“SoniVie” or […]
TEL AVIV, Israel, July 13, 2022 /PRNewswire/ — SoniVie, an Israeli company developing a novel proprietary Therapeutic Intra-Vascular Ultrasound (TIVUS™) System to treat a variety of hypertensive disorders, announced that on May 30th 2022 the first patient was treated with its Renal Artery Denervation […]
TEL AVIV, Israel, June 20, 2022 /PRNewswire/ — SoniVie, an Israeli company developing a novel proprietary Therapeutic Intra-Vascular Ultrasound System (TIVUS™) to treat a variety of hypertensive disorders, announced that on May 5th 2022 the U.S. Food and Drug Administration granted IDE approval for its […]
– SoniVie Acquires New Intellectual Property and Other Assets from Cardiosonic Moving TIVUS into New Therapeutic Areas Beyond Pulmonary Hypertension – TEL AVIV, Israel, Dec. 09, 2020 (GLOBE NEWSWIRE) — SoniVie, an Israeli company developing a novel proprietary Therapeutic Intra-Vascular […]
– Designation facilitates more rapid approval and reimbursement for a breakthrough technology that offers significant advantages over current PAH treatment options – TEL AVIV, ISRAEL (PRWEB) SEPTEMBER 06, 2019 SoniVie, an Israeli company developing a novel system for the treatment of […]
